Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Export

@article{citeulike:2230765, abstract = {AIMS/HYPOTHESIS: Recent studies have shown that the inflammatory process is involved in the pathogenesis of diabetic nephropathy. Fourteen-membered ring macrolides, including erythromycin, have anti-inflammatory, as well as antibacterial effects. The aim of this study was to investigate the renoprotective effects of erythromycin in streptozotocin (STZ)-induced diabetic rats. METHODS: STZ-induced diabetic rats were treated orally with erythromycin (5 mg/kg body weight) or vehicle every day for 8 weeks. To evaluate the effect of erythromycin treatment, we measured urinary albumin excretion, and examined the following in the kidney: histological changes, the expression of intercellular adhesion molecule-1 (ICAM-1), macrophage infiltration, and nuclear factor-kappa B (NF-kappaB) activity. RESULTS: Erythromycin significantly reduced urinary albumin excretion without affecting blood glucose levels and blood pressure. Erythromycin also attenuated glomerular hypertrophy, mesangial expansion, macrophage infiltration and ICAM-1 expression in renal tissues. The expression of the gene encoding TGFB1 (also known as TGF-beta1), type IV collagen protein production and NF-kappaB activity in renal tissues were increased in diabetic rats and reduced by erythromycin treatment. CONCLUSIONS/INTERPRETATION: Erythromycin prevented renal injuries without changes of blood glucose levels and blood pressure in experimental diabetic rats. These results suggest that the renoprotective effects of erythromycin are based on its anti-inflammatory effect via suppression of NF-kappaB activation. Modulation of microinflammation with erythromycin may provide a new approach for diabetic nephropathy.}, address = {Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.}, author = {Tone, A. and Shikata, K. and Sasaki, M. and Ohga, S. and Yozai, K. and Nishishita, S. and Usui, H. and Nagase, R. and Ogawa, D. and Okada, S. and Shikata, Y. and Wada, J. and Makino, H.}, citeulike-article-id = {2230765}, citeulike-linkout-0 = {http://dx.doi.org/10.1007/s00125-005-1945-6}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/16231067}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=16231067}, doi = {10.1007/s00125-005-1945-6}, issn = {0012-186X}, journal = {Diabetologia}, keywords = {dn, erythromycin, inflammation, nfkb, rat, stz}, month = {November}, number = {11}, pages = {2402--2411}, posted-at = {2008-01-14 15:08:47}, priority = {2}, title = {Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats.}, url = {http://dx.doi.org/10.1007/s00125-005-1945-6}, volume = {48}, year = {2005} }

TY - JOUR ID - citeulike:2230765 L3 - citeulike-article-id:2230765 N2 - AIMS/HYPOTHESIS: Recent studies have shown that the inflammatory process is involved in the pathogenesis of diabetic nephropathy. Fourteen-membered ring macrolides, including erythromycin, have anti-inflammatory, as well as antibacterial effects. The aim of this study was to investigate the renoprotective effects of erythromycin in streptozotocin (STZ)-induced diabetic rats. METHODS: STZ-induced diabetic rats were treated orally with erythromycin (5 mg/kg body weight) or vehicle every day for 8 weeks. To evaluate the effect of erythromycin treatment, we measured urinary albumin excretion, and examined the following in the kidney: histological changes, the expression of intercellular adhesion molecule-1 (ICAM-1), macrophage infiltration, and nuclear factor-kappa B (NF-kappaB) activity. RESULTS: Erythromycin significantly reduced urinary albumin excretion without affecting blood glucose levels and blood pressure. Erythromycin also attenuated glomerular hypertrophy, mesangial expansion, macrophage infiltration and ICAM-1 expression in renal tissues. The expression of the gene encoding TGFB1 (also known as TGF-beta1), type IV collagen protein production and NF-kappaB activity in renal tissues were increased in diabetic rats and reduced by erythromycin treatment. CONCLUSIONS/INTERPRETATION: Erythromycin prevented renal injuries without changes of blood glucose levels and blood pressure in experimental diabetic rats. These results suggest that the renoprotective effects of erythromycin are based on its anti-inflammatory effect via suppression of NF-kappaB activation. Modulation of microinflammation with erythromycin may provide a new approach for diabetic nephropathy. IS - 11 JF - Diabetologia SN - 0012-186X AD - Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan. EP - 2411 TI - Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. VL - 48 SP - 2402 KW - dn KW - erythromycin KW - inflammation KW - nfkb KW - rat KW - stz AU - Tone, A AU - Shikata, K AU - Sasaki, M AU - Ohga, S AU - Yozai, K AU - Nishishita, S AU - Usui, H AU - Nagase, R AU - Ogawa, D AU - Okada, S AU - Shikata, Y AU - Wada, J AU - Makino, H PY - 2005/11// UR - http://dx.doi.org/10.1007/s00125-005-1945-6 ER -